413 related articles for article (PubMed ID: 29075104)
1. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
2. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
3. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA; De Giorgi U; Verzoni E; Maiello E; Procopio G; Conteduca V; Di Maio M;
Target Oncol; 2024 Jan; 19(1):1-11. PubMed ID: 37993604
[TBL] [Abstract][Full Text] [Related]
4. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
5. Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials.
Bowling GC; Swargaloganathan P; Heintz C; Madan RA; Eldhose B; Dobi A; Chesnut GT
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835597
[TBL] [Abstract][Full Text] [Related]
6. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials.
Wang C; Li J
J Clin Pharm Ther; 2021 Jun; 46(3):571-584. PubMed ID: 33421183
[TBL] [Abstract][Full Text] [Related]
7. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Liu Y; Meng J; Wang G
Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
[TBL] [Abstract][Full Text] [Related]
8. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
9. A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients.
Lee CS; Hernandez J; Liang C; Leung A; Stefanov DG; Cheng K; John V
J Pharm Pract; 2023 Oct; 36(5):1134-1141. PubMed ID: 35439094
[No Abstract] [Full Text] [Related]
10. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Sui JD; Wang Y; Wan Y; Wu YZ
Drug Des Devel Ther; 2018; 12():1645-1657. PubMed ID: 29922039
[TBL] [Abstract][Full Text] [Related]
11. Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis.
Jiang X; Xiong F; Fu Q; Peng H; Jing Y; Rexiti K; Wei X; Tao S
Int J Colorectal Dis; 2022 Jul; 37(7):1525-1534. PubMed ID: 35780257
[TBL] [Abstract][Full Text] [Related]
12. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
Abdel-Rahman O; ElHalawani H
Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
[TBL] [Abstract][Full Text] [Related]
13. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
14. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
[TBL] [Abstract][Full Text] [Related]
15. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
[TBL] [Abstract][Full Text] [Related]
16. Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis.
Wang P; Zhao R; Jin X; Zhou X; Xie X
Cancer Invest; 2024 Mar; 42(3):260-273. PubMed ID: 38588003
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
[TBL] [Abstract][Full Text] [Related]
18. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
Ruiz-Schutz VC; Gomes LM; Mariano RC; de Almeida DVP; Pimenta JM; Dal Molin GZ; Kater FR; Yamamura R; Correa Neto NF; Maluf FC; Schutz FA
Crit Rev Oncol Hematol; 2019 Sep; 141():163-173. PubMed ID: 31306986
[TBL] [Abstract][Full Text] [Related]
19. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis.
Dai MF; Wang X; Xin WX; Kong SS; Xu WB; Ding HY; Fang L
Expert Rev Anticancer Ther; 2024 May; ():1-10. PubMed ID: 38761169
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
